L2L Microarray Analysis Tool
Results for H02AB.profile.d50
| Results summary | View all lists in L2L MDB | View all genes in H02AB.profile.d50 |
| List Name | Description | Total probes |
Expected matches |
Actual matches |
Fold Enrichment |
Binomial p-value |
|---|---|---|---|---|---|---|
| alk5_hmvec_2hr_up | Up-regulated 2 hr following constitutive activation of TGFbeta receptor ALK5,, which activates the Smad2/3 pathway, in human microvessel endothelial cells (HMVEC). | 347 | 0.86 | 7 | 8.16 | 3.07e-05 |
| alk5_hmvec_4hr_up | Up-regulated 4 hr following constitutive activation of TGFbeta receptor ALK5,, which activates the Smad2/3 pathway, in human microvessel endothelial cells (HMVEC). | 347 | 0.86 | 7 | 8.16 | 3.07e-05 |
| cmv_all_dn | Downregulated at any timepoint following infection of primary human foreskin fibroblasts with CMV | 213 | 0.53 | 5 | 9.50 | 2.10e-04 |
| uvc_low_a2_up | Up-regulated at 6-12 hours following treatment of WS1 human skin fibroblasts with UVC at a low dose (10 J/m^2) (cluster a2) | 17 | 0.04 | 2 | 47.59 | 8.11e-04 |
| hdaci_colon_cluster9 | Regulated by TSA, butyrate and/or curcumin in SW260 colon carcinoma cells (Cluster 9, associated with histone hyperAc) | 78 | 0.19 | 3 | 15.56 | 1.00e-03 |
| cited1_ko_wt_dn | Down-regulated in pubertal mammary glands from CITED1 knockout mice, which display disturbed mammary development, versus wild-type controls | 21 | 0.05 | 2 | 38.53 | 1.24e-03 |
| cmv_hcmv_timecourse_16hrs_up | Up-regulated in fibroblasts following infection with human cytomegalovirus (at least 3-fold, with Affymetrix change call, in at least two consectutive timepoints), with maximum change at 16 hours | 93 | 0.23 | 3 | 13.05 | 1.66e-03 |
| hdaci_colon_but24hrs_up | Upregulated by butyrate at 24 hrs in SW260 colon carcinoma cells | 95 | 0.23 | 3 | 12.77 | 1.76e-03 |
| microrna_vertebrate | Predicted MicroRNA targets conserved across human, mouse, rat, zebrafish and fugu | 214 | 0.53 | 4 | 7.56 | 2.10e-03 |
| cis_xpc_dn | Reduced expression in XPC-defective fibroblasts, compared to normal fibroblasts, following treatment with cisplatin | 363 | 0.90 | 5 | 5.57 | 2.27e-03 |
| tzd_adip_dn | Downregulated by treatment of mature murine adipocytes with the PPARgamma agonist troglitazone | 29 | 0.07 | 2 | 27.90 | 2.37e-03 |
| baf57_bt549_dn | Down-regulated following stable re-expression of BAF57 in Bt549 breast cancer cells that lack functional BAF57 | 554 | 1.37 | 6 | 4.38 | 2.83e-03 |
| hdaci_colon_but_up | Upregulated by butyrate at any timepoint up to 48 hrs in SW260 colon carcinoma cells | 233 | 0.58 | 4 | 6.94 | 2.85e-03 |
| uvc_low_all_up | Up-regulated at any timepoint following treatment of WS1 human skin fibroblasts with UVC at a low dose (10 J/m^2) (clusters a1-a4) | 33 | 0.08 | 2 | 24.52 | 3.07e-03 |
| inos_all_dn | Downregulated following iNOS induction in hepatocytes (Tables 3-17) | 117 | 0.29 | 3 | 10.37 | 3.18e-03 |
| hdaci_colon_but48hrs_up | Upregulated by butyrate at 48 hrs in SW260 colon carcinoma cells | 135 | 0.33 | 3 | 8.99 | 4.75e-03 |
| cmv_24hrs_dn | Downregulated at 24hrs following infection of primary human foreskin fibroblasts with CMV | 140 | 0.35 | 3 | 8.67 | 5.25e-03 |
| idx_tsa_dn_cluster6 | Strongly down-regulated at 2 hours during differentiation of 3T3-L1 fibroblasts into adipocytes with IDX (insulin, dexamethasone and isobutylxanthine), vs. fibroblasts treated with IDX + TSA to prevent differentiation (cluster 6) | 48 | 0.12 | 2 | 16.86 | 6.39e-03 |
| prmt5_kd_up | Up-regulated by stable RNAi knock-down of PRMT5 in NIH 3T3 cells | 306 | 0.76 | 4 | 5.29 | 7.41e-03 |
| xpb_ttd-cs_up | Up-regulated in XPB/TTD fibroblasts (expressing XPB-A355C), compared to XPB/CS fibroblasts (expressing XPB-T296C) | 57 | 0.14 | 2 | 14.19 | 8.91e-03 |